{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"CRp"}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"}],"units":"Participants"}],"description":"Complete Response (CR) is required bone marrow blasts ≤5% and recovery of normal hematopoiesis with an absolute neutrophil count (ANC) of 1\\*10\\^9/L or more and platelet count of 100\\*10\\^9/L or more; and a complete response without platelets (CRp) is the same criteria as CR but with platelet counts from 20\\*10\\^9/L to less than 100\\*10\\^9/L.","groups":[{"description":"Cytarabine 1.5 g/m\\^2 and Idarubicin 12 mg/m\\^2 intravenous (IV) continuously on days 1-3 (or 1-4), with Oral Tipifarnib 200/300 twice daily on days 1-21, repeats every 21 days.","id":"OG000","title":"Idarubicin, Cytarabine + Tipifarnib"}],"paramType":"NUMBER","populationDescription":"Analysis was per protocol.","reportingStatus":"POSTED","timeFrame":"21 Day Cycle","title":"Number of Participants With Complete Response","type":"PRIMARY","unitOfMeasure":"Participants"}